Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 4
2017 1
2018 6
2019 6
2020 10
2021 7
2022 7
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Among authors: cejalvo jm. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. Schettini F, et al. Among authors: cejalvo jm. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. NPJ Breast Cancer. 2021. PMID: 33397968 Free PMC article.
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. Pérez-Núñez I, et al. Among authors: cejalvo jm. Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17. Nat Cancer. 2022. PMID: 35301507
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: cejalvo jm. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. Adam-Artigues A, et al. Among authors: cejalvo jm. Cancer Treat Rev. 2023 Dec;121:102639. doi: 10.1016/j.ctrv.2023.102639. Epub 2023 Oct 7. Cancer Treat Rev. 2023. PMID: 37864955 Free article. Review.
Immunological Landscape of HER-2 Positive Breast Cancer.
Moragon S, Hernando C, Martinez-Martinez MT, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo JM. Moragon S, et al. Among authors: cejalvo jm. Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. Cancers (Basel). 2022. PMID: 35804943 Free PMC article. Review.
In the literature: February 2020.
Roda D, Gambardella V, Cejalvo JM, Cervantes A. Roda D, et al. Among authors: cejalvo jm. ESMO Open. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. ESMO Open. 2020. PMID: 32079625 Free PMC article. No abstract available.
Personalized Medicine: Recent Progress in Cancer Therapy.
Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. Cancers (Basel). 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. Cancers (Basel). 2020. PMID: 32325878 Free PMC article. Review.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: cejalvo jm. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano Á, García-Sáenz JÁ, Cejalvo JM, Herranz J, Torres R, Haba-Rodriguez J, Ayala F, Gómez H, Rojo F, Nielsen TO, Martin M. Asleh K, et al. Among authors: cejalvo jm. Clin Cancer Res. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. Clin Cancer Res. 2023. PMID: 36346687 Free PMC article. Clinical Trial.
50 results